Novo-Nordisk is a healthcare company focuses on diabetes care. Co. is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products and has two segments: diabetes and obesity care and biopharm. Co. has one diabetes product portfolios, including insulin, a portfolio of modern insulin and human insulin as well as a portfolio of GLP-1 receptor agonists administered both via subcutaneous injection and as a tablet. In addition, Co. also has a position within hemophilia and growth hormone therapy, and Co.'s product to treat obesity, Saxenda®. Co. manufactures and markets pharmaceutical products and services. The NVO stock yearly return is shown above.
The yearly return on the NVO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the NVO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|